Exclusive Online Content
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
Ensysce Biosciences, Inc. recently announced receipt of notice from the US FDA that it has granted Breakthrough Therapy Designation (BTD) for PF614-MPAR. A next-generation opioid, PF614-MPAR represents a major….
Biognosys Expands US Footprint With New Proteomics CRO Facility in Massachusetts
Biognosys recently announced the operational readiness of its new proteomics facility in Massachusetts. This US expansion facilitates access to select proteomics contract research organization (CRO) services for our US biopharma customers…..
Alcami Announces Acquisition of West-Coast Based Pacific Pharmaceutical Services
Alcami Corporation recently announced it has completed the acquisition of Pacific Pharmaceutical Services, Inc. (PPS), a preferred provider of….
Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development & Manufacturing Organization
Kindeva Drug Delivery recently announced it has acquired Summit Biosciences Inc., an intranasal drug delivery contract development and manufacturing organization, from its founding….
Credence MedSystems Announces a Significant Milestone Toward Scaling Manufacturing Capabilties
Credence MedSystems recently announced it has successfully completed Factory Acceptance Testing (FAT) for production of its Companion® injection device platform on the company’s new Clinical Assembly Line…..
Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith for $210 Million in Transaction to Fuel Global Expansion
Bora Pharmaceuticals Co., Ltd. recently announced its Board of Directors has approved the acquisition of Upsher-Smith Laboratories, Inc., a generics manufacturer based in Minnesota, US, from shareholders, Sawai….
Abzena Launches AbZelect Platforms for Improving Cell Line Development Efficiency on the Pathway to IND
Abzena has launched AbZelect and AbZelectPRO cell line development (CLD) platforms for accelerating the generation of production cell lines for manufacture of antibodies and recombinant proteins. The platforms will….
Intravacc Awarded CARB-X Funding to Develop Vaccine That Prevents Gonorrhea Infections
Intravacc recently announced it has been awarded a funding that may total $633K from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) a global non-profit organization, for the….
Emergex Announces R&D Collaboration With DEKA Research & Development Corp. for Assessment of Emergex’s Immunotherapeutic Candidates With DEKA’s Intradermal Therapeutic Applicator
Emergex Vaccines Holding Limited recently announced it has entered into an agreement with DEKA to assess the compatibility of Emergex’s immunotherapeutic candidates with the DEKA Intradermal Therapeutic Applicator…..
Contract Packaging Predicted to See High Growth in 2024 Ahead of Pharmapack Europe
The outlook for pharma services in 2024 is continuing to improve, with 94% of the industry either “moderately positive” (37%) or “highly positive” (37%) on growth for contract packaging in….
STADA & Alvotech Secure Approval for Europe’s First Ustekinumab Biosimilar to Stelara
Partners STADA and Alvotech recently announced the European Commission issued a marketing authorization for Uzpruvo (AVT04), a biosimilar candidate to Stelara (ustekinumab). The centralized marketing….
Lexaria Bioscience Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug Delivery Platform
Lexaria Bioscience Corp. recently announced its placement in an editorial published by NetworkNewsWire (NNW), one of 60+ brands within the….
Enzene Biosciences Launches its First Manufacturing Base in the US, With Additional Plans to Establish Continuous Manufacturing Operations at its New Jersey Site
Widely recognized as a pioneer in continuous manufacturing, Pune-based Contract Development & Manufacturing Organization (CDMO), Enzene Biosciences has announced the launch of its first manufacturing site in the US, located in….
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study for Drug-Device combination Program
Biora Therapeutics, Inc. recently announced initiation of its Phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers. BT-600 is a drug-device combination program consisting of the orally….
Sitryx Announces Collaboration Partner Lilly Has Commenced Phase 1 Study of SIT-011 for Chronic Autoimmune & Inflammatory Diseases
Sitryx Therapeutics recently announced Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and….
Gerresheimer & Aptar Digital Health Collaborate to Develop Integrated Solution for Cancer Therapy
Gerresheimer and Aptar Digital Health recently announced they will collaborate to develop an integrated solution for cancer therapy management. As part of this collaboration….
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
BriaCell Therapeutics Corp. recently released transformational images of the recently reported remarkable responder in the Phase 2 study of BriaCell’s Bria-IMT combination regimen…..
Elektrofi & Janssen Biotech Enter Worldwide Collaboration & License Agreement to Exclusively Develop Up to Five Programs Utilizing Elektrofi’s Formulation Technology
Elektrofi, Inc. recently announced it has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company. This collaboration will initially focus on developing an at home….
Ampersand Biomedicines Acquires AbCheck to Accelerate Platform and Product Development
Acquisition amplifies Ampersand’s in-house capabilities to generate AND-Body Therapeutics – programmed biologics across a broad range of diseases….
4DMT & Arbor Biotechnologies Establish Partnership to Co-Develop & Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics for up to six product candidates in CNS….
